Markets
CMA

Concordia Says UK's CMA is Investigating Its International Segment And Certain of Its Products

Concordia International ( CXRX ), a Canada-based pharmaceutical company, said Wednesday that its International segment and certain of its products are part of an investigation into new issues in the UK pharmaceutical sector by the UK Competition and Markets Authority ( CMA ).

The company said the investigation is at an early, information-gathering stage and that the CMA has confirmed that, at this time, it has not reached any conclusions on whether competition law has been infringed.

The company also said that the investigation includes matters that pre-date its ownership of the International segment. Concordia acquired the International segment as a result of its transaction to purchase Amdipharm Mercury Limited, which closed on Oct. 21, 2015.

Concordia said it will work to resolve the matter with the CMA.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CMA

Other Topics

ETFs